Strand Life Sciences, a subsidiary of Reliance Industries, is looking to expand its blood-based cancer screening test, CancerSpot, into overseas markets. It is primarily targeting the US, Southeast Asia and West Asia, among other regions.
The company is pursuing US Food and Drug Administration (FDA) approval for the test and expects the regulatory process to reach a key milestone around February-March next year. The US would be its next export market once the approval comes through, a company representative said.
“In most regions of the world, one doesn’t need it (regulatory approval to operate). Our aspiration is global. There is good opportunity in Southeast Asia, West Asia and other parts of the world, which we will be aggressively pursuing,” Dr Ramesh Hariharan, chief executive officer (CEO) of Strand Life Sciences, said.
Regulatory requirements vary across markets, and the company will pursue approvals wherever required. Hariharan said such clearances also help build confidence among clinicians and other stakeholders.
CancerSpot uses genome sequencing, DNA methylation analysis and artificial intelligence (AI) to identify patterns in DNA fragments circulating in the blood that may be associated with cancer.
The test has demonstrated the ability to screen for 14 types of cancer.
The company is also looking to make the test more affordable in India. It is currently priced at up to ₹25,000 for patients, with Strand targeting a price of less than ₹10,000 over the next few years.
The longer-term ambition is to bring the cost down further and make the test a part of routine preventive health checks. However, the company has not specified a timeline for reaching that price point.
Reducing costs will depend on improvements in sequencing technology, procurement and laboratory processes, as well as higher volumes.
The company is also working to build awareness among doctors and patients as it looks to scale up. It is in discussions with hospitals and academic institutions on collaborations, including larger clinical studies.
Hospitals are important to the process because a positive screening result needs follow-up investigations and clinical care.
CancerSpot is a screening test and does not provide a definitive cancer diagnosis.
A positive result needs to be followed up by targeted imaging or endoscopy and, where indicated, a biopsy to confirm the presence of cancer.
The company’s four-year study, conducted across 43 hospitals in India and involving around 1,400 participants, included about 950 people with cancer and 450 healthy individuals.
In an independent set of participants, the test recorded a false-positive rate of 1.4 per cent. The study reported that it detected 72 per cent of cancers, including around 65-70 per cent at early stages.
Strand said the test is intended to complement, rather than replace, established screening methods, such as mammography and colonoscopy.
It covers several cancer types for which routine screening options are limited or unavailable.













